Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production.
A defect in erythropoietin (EPO) production has been advocated as being the main cause of anemia presented at time of diagnosis or during treatment by adults with solid tumors. On the basis of this defect, anemic cancer patients, both adults and children, have been treated with recombinant human EPO (rHuEPO). To further elucidate the pathophysiology of anemia in children with cancer, we measured serum soluble transferrin receptor (sTfR), a quantitative marker of erythropoiesis, and serum EPO at time of diagnosis and during chemotherapy in children suffering from solid tumor or leukemia. We determined serum EPO in 111 children (55 leukemia, 56 solid tumors) at time of diagnosis. In the last 44 patients (23 leukemia and 21 solid tumors), sTfR levels were also measured. Serum EPO together with sTfR levels were also determined in 60 children receiving chemotherapy (29 leukemia, 31 solid tumors). These results were compared with those obtained from appropriate control groups. In all patients, we found a highly significant correlation between the logarithm of EPO (log[EPO]) and the hemoglobin (Hb) level. In all subsets of patients, sTfR levels were inappropriately low for the degree of anemia. Neither leukemic nor solid tumor groups showed a significant inverse relationship between log(sTfR) and the Hb level as would be expected in anemic patients with appropriate marrow response. Thus, in children with cancer, anemia is associated with a decreased total bone marrow erythropoietic activity which, in contrast to what has been reported in anemic cancer adults, is not related to defective EPO production.
Laboratory of Hematology and of Clinical Chemistry, Brugmann University Hospital, Brussels, Belgium.
F
F
Corazza
Y
Y
Beguin
P
P
Bergmann
M
M
André
A
A
Ferster
C
C
Devalck
P
P
Fondu
M
M
Buyse
E
E
Sariban
D000293:Adolescent; D000740:Anemia / Q000097:blood / Q000209:etiology* / Q000473:pathology; D001854:Bone Marrow Cells / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D015672:Erythroid Precursor Cells / Q000473:pathology; D004920:Erythropoiesis; D004921:Erythropoietin / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011990:Receptors, Transferrin / Q000097:blood
D006454:Hemoglobins; D011990:Receptors, Transferrin; D004921:Erythropoietin